Skip to main content

Table 2 The clinical performance for ≥ CIN2 detection of HPV detected in cervix, upper vagina, lower vagina, and perineum samples

From: The features of high-risk human papillomavirus infection in different female genital sites and impacts on HPV-based cervical cancer screening

Sample sources

Sensitivity (%; 95% CI)

Specificity (%; 95% CI)

PPV (%; 95% CI)

AUC

Cervix

100.00(98.40–100.00)

53.62(48.96–58.22)

18.65(14.33–23.92)

0.768(0.720–0.817)

Upper vagina

97.87(88.89–99.62)

37.78(33.39–42.39)*

14.33(10.92–18.59)

0.678(0.615–0.741)

Lower vagina

95.74(85.75–98.83)

38.91(34.48–43.54)*

14.29(10.85–18.58)

0.673(0.608–0.738)

Perineum

91.49(80.07–96.64)*

47.96(43.34–52.62)

15.75(11.91–20.54)

0.697(0.632–0.763)

  1. Note: * indicates a statistically significant difference between this site and cervix (p value < 0.05)